Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II

• US 10,111,849 B2
• Filed: 03/21/2017
• Issued: 10/30/2018
• Est. Priority Date: 05/01/2000
• Status: Expired due to Fees

• Current Assignee: Accela Incorporated (Piksel Incorporated)
• Original Assignee: Accela Incorporated (Piksel Incorporated)
• Inventors: Henderson, Samuel T.
• Primary Examiner(s): Cruz, Kathrien A
• Application Number:
  US15/465,171
• Publication Number:
  US 20180036274A1
• Time in Patent Office: 588 Days
• Field of Search: 514557
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/25 with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer'"'"'s type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

Claims

1. A method of treating loss of cognitive function caused by Alzheimer'"'"'s disease or Mild Cognitive Impairment in a patient that is ApoE4(−

), the method comprising;

orally administering a dosage unit of medium chain triglyceride to said patient in need thereof such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.1 to 50 mM causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function,

wherein the dosage unit is given in a single dose.

2. The method of claim 1, wherein the blood level of D-beta-hydroxybutyrate is raised to about 0.2 to 20 mM.

3. The method of claim 1, wherein the blood level of D-beta-hydroxybutyrate is raised to about 0.3 to 5 mM.

4. The method of claim 1, wherein the blood level of D-beta-hydroxybutyrate is raised to about 0.5 to 2 mM.

5. The method of claim 1, wherein the blood level of D-beta-hydroxybutyrate is raised to about 1 to 10 mM.

6. The method of claim 1, wherein the loss of cognitive function is caused by Alzheimer'"'"'s Disease.

7. A method of treating loss of cognitive function caused by Alzheimer'"'"'s disease or mild cognitive impairment in a patient that is ApoE4(−

), the method comprising;

orally administering a dosage unit of medium chain triglyceride to said patient in need thereof such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.2 to 20 mM causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function.

8. The method of claim 7, wherein the blood level of D-beta-hydroxybutyrate is raised to about 0.3 to 5 mM.

9. The method of claim 7, wherein the blood level of D-beta-hydroxybutyrate is raised to about 0.5 to 2 mM.

10. The method of claim 7, wherein the blood level of D-beta-hydroxybutyrate is raised to about 1 to 10 mM.

11. The method of claim 7, wherein the dosage unit is given in a single dose.

12. A method of treating loss of cognitive function caused by reduced neuronal metabolism in a patient that is ApoE4(−

), the method comprising;

orally administering a dosage unit of medium chain triglyceride (MCT) to said patient in need thereof, wherein said MCT are administered at a dose of about 3.4 g per day to about 680 g per day causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function,

wherein the dosage unit is given in a single dose.

13. The method of claim 12, wherein the MCT are administered in a dose of about 17 g/day to 340 g/day.

14. The method of claim 12, wherein the MCT are administered in a dose of about 34 g/day to 136 g/day.

15. The method of claim 12, wherein the loss of cognitive function is caused by Alzheimer'"'"'s Disease.

16. The method of claim 12, wherein the MCT are administered in a dose of about 17 g per day to about 34 g per day.